AbbVie Inc. - Rule
2.10 Announcement - Relevant Securities in Issue
NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO
OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
NORTH CHICAGO, Ill.,
Sept. 18, 2019 /PRNewswire/
-- In accordance with Rule 2.10 of the Irish Takeover Panel
Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of
September 16, 2019 its issued share
capital, excluding treasury shares, is comprised of 1,478,779,037
shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded
on the NYSE and Chicago Stock Exchange under the symbol ABBV.
The International Securities Identification Number (ISIN) of the
AbbVie common stock is US00287Y1091.
AbbVie confirms that, as of the close of business on
September 16, 2019, there were
outstanding 6,826,241 options to purchase shares of common stock
(the "Stock Options"), 7,947,357 restricted stock units (the
"Restricted Stock Units") and 2,386,702 performance shares (the
"Performance Shares"). Upon exercise, each Stock Option entitles
the holder to purchase one share of common stock at the applicable
exercise price. Upon vesting, each Restricted Stock Unit and
Performance Share entitles the holder to receive one share of
common stock.
The Directors of AbbVie Inc. accept
responsibility for the information contained in this announcement.
To the best of their knowledge and belief (having taken all
reasonable care to ensure such is the case), the information
contained in this announcement is in accordance with the facts and
does not omit anything likely to affect the import of such
information.
Any holder of 1% or more of any class
of relevant securities of AbbVie Inc. may have disclosure
obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997,
Takeover Rules 2013.
CONTACT: Adelle Infante,
1-847-938-8745